Advertisement
Journal Home
Search for
Advanced Search - MEDLINE - My Recent Searches - My Saved Searches - Search Tips
More periodicals:

1,576 Periodical Search Results

You searched for "clinical" AND "benefit" within European Journal of Cancer

New Search | Edit Search | Save Search | Save Search as an E-mail Alert

  Viewing 1-20  of 1,576 results   Next 20>

Results Page:  [1]  2  3  4  5  6  7  >

display abstract citation download email a colleague
Display:

  1. Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point? , 22 June 2009
    Pavlo Ohorodnyk, Elizabeth A. Eisenhauer, Christopher M. Booth
    European Journal of Cancer
    September 2009 (Vol. 45, Issue 13, Pages 2249-2252)
    Abstract | Full Text | Full-Text PDF (101 KB)

  1. A new anti-cancer drug in the market: Good news for investors or for patients? , 31 July 2008
    Giovanni Apolone, Giovanni Tafuri, Francesco Trotta, Silvio Garattini
    European Journal of Cancer
    September 2008 (Vol. 44, Issue 13, Pages 1786-1788)
    Full Text | Full-Text PDF (108 KB)

  1. Targeted therapies in the treatment of advanced/metastatic NSCLC , 14 July 2009
    A.G. Pallis, L. Serfass, R. Dziadziuszko, J.P. van Meerbeeck, D. Fennell, D. Lacombe, J. Welch, C. Gridelli
    European Journal of Cancer
    September 2009 (Vol. 45, Issue 14, Pages 2473-2487)
    Abstract | Full Text | Full-Text PDF (236 KB)

  1. Do we need prognostic factors in nodal-negative breast cancer? Arbiter:
    D.F Hayes
    European Journal of Cancer
    February 2000 (Vol. 36, Issue 3, Pages 302-306)
    Full Text | Full-Text PDF (129 KB)

  1. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer , 22 July 2008
    Florian Lordick, Theo Ruers, Daniela E. Aust, Laurence Collette, Robert J Downey, Mostafa El Hajjam, Patrick Flamen, Karen Haustermans, David Ilson, Catherine Julié, Bernd Joachim Krause, Hartwig Newiger, Katja Ott, Arnaud Roth, Eric Van Cutsem, Wolfgang A. Weber, Manfred P. Lutz
    European Journal of Cancer
    September 2008 (Vol. 44, Issue 13, Pages 1807-1819)
    Abstract | Full Text | Full-Text PDF (572 KB)

  1. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer
    Eriko Tokunaga, Akemi Kataoka, Yasue Kimura, Eiji Oki, Kojiro Mashino, Kojiro Nishida, Tadashi Koga, Masaru Morita, Yoshihiro Kakeji, Hideo Baba, Shinji Ohno, Yoshihiko Maehara
    European Journal of Cancer
    March 2006 (Vol. 42, Issue 5, Pages 629-635)
    Abstract | Full Text | Full-Text PDF (192 KB)

  1. Lost in translation: Problems and pitfalls in translating laboratory observations to clinical utility , 03 November 2008
    Richard Simon
    European Journal of Cancer
    December 2008 (Vol. 44, Issue 18, Pages 2707-2713)
    Abstract | Full Text | Full-Text PDF (131 KB)

  1. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women
    J.F.R. Robertson, R.W. Blamey
    European Journal of Cancer
    May 2003 (Vol. 39, Issue 7, Pages 861-869)
    Abstract | Full Text | Full-Text PDF (170 KB)

  1. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma
    A. Lafuma, B. Dreno, M. Delaunay, C. Emery, F. Fagnani, K. Hieke, J.-J. Bonerandi, J.-J. Grob, for the French Cooperative Group on Melanoma 1 French cooperative group on melanoma: P. de la Salmonière, D. Cupissol, B. Guillot, P. Souteyrand, B. Sassolas, J.P. Cesarini, S. Lionnet, C. Lok, C. Chastang, E. Mansat, J.P. Lacour, L Thomas, M. Beylot Barry, J.F. Truchelet, P. Chemaly, L. Machet, J. Meynadier, A. Thyss, M.F. Avril, C. Vilmer, F. Prigent, J. Chevrant Breton, S. Dalac, P. Fargeot, P. Amblard, R. Schaerrer, M. Geniaux, M. Caubel, G. Guillet, M. Baccard, J.C. Guillaume, C. Pauwels, JC. Barats, P. Wolkenstein, L. Cals, R. Laurent, C. Beylot, G. Lorette, J.P. Denoeux, I. Masson, P. Royer, M. Masson.
    European Journal of Cancer
    February 2001 (Vol. 37, Issue 3, Pages 369-375)
    Abstract | Full Text | Full-Text PDF (168 KB)

  1. Methodological issues in the economic analysis of cancer treatments
    Paul Tappenden, Jim Chilcott, Sue Ward, Simon Eggington, Daniel Hind, Silvia Hummel
    European Journal of Cancer
    November 2006 (Vol. 42, Issue 17, Pages 2867-2875)
    Abstract | Full Text | Full-Text PDF (225 KB)

  1. Vinorelbine in androgen-independent metastatic prostatic carcinoma—a phase II study
    R Morant, S.-F Hsu Schmitz, J Bernhard, B Thürlimann, M Borner, M Wernli, F Egli, P Forrer, A Streit, E Jacky, S Hanselmann, J Bauer, F Hering, H.-P Schmid, for the Swiss Group for Clinical Cancer Research (SAKK)
    European Journal of Cancer
    August 2002 (Vol. 38, Issue 12, Pages 1626-1632)
    Abstract | Full Text | Full-Text PDF (130 KB)

  1. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study , 27 May 2009
    Giorgio V. Scagliotti, Keunchil Park, Shekar Patil, Janusz Rolski, Tuncay Goksel, Renato Martins, Steven J.M. Gans, Carla Visseren-Grul, Patrick Peterson
    European Journal of Cancer
    September 2009 (Vol. 45, Issue 13, Pages 2298-2303)
    Abstract | Full Text | Full-Text PDF (236 KB)

  1. Does biomodulation of 5-fluorouracil improve results? Pro:
    A.F Sobrero
    European Journal of Cancer
    February 1999 (Vol. 35, Issue 2, Pages 186-189)
    Full Text | Full-Text PDF (63 KB)

  1. Validation of novel imaging methodologies for use as cancer clinical trial end-points , 17 December 2008
    D.J. Sargent, L. Rubinstein, L. Schwartz, J.E. Dancey, C. Gatsonis, L.E. Dodd, L.K. Shankar
    European Journal of Cancer
    January 2009 (Vol. 45, Issue 2, Pages 290-299)
    Abstract | Full Text | Full-Text PDF (160 KB)

  1. New science-based endpoints to accelerate oncology drug development
    Gary J. Kelloff, Caroline C. Sigman
    European Journal of Cancer
    March 2005 (Vol. 41, Issue 4, Pages 491-501)
    Abstract | Full Text | Full-Text PDF (157 KB)

  1. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial
    C. Gridelli, C. Manegold, P. Mali, M. Reck, L. Portalone, O. Castelnau, R. Stahel, D. Betticher, M. Pless, J. Terrassa Pons, D. Aubert, J.-P. Burillon, Y. Parlier, F. De Marinis
    European Journal of Cancer
    November 2004 (Vol. 40, Issue 16, Pages 2424-2431)
    Abstract | Full Text | Full-Text PDF (298 KB)

  1. Recommendations for the assessment of progression in randomised cancer treatment trials , 22 December 2008
    J.E. Dancey, L.E. Dodd, R. Ford, R. Kaplan, M. Mooney, L. Rubinstein, L.H. Schwartz, L. Shankar, P. Therasse
    European Journal of Cancer
    January 2009 (Vol. 45, Issue 2, Pages 281-289)
    Abstract | Full Text | Full-Text PDF (139 KB)

  1. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil
    H. Burris, A.M. Storniolo
    European Journal of Cancer
    January 1997 (Vol. 33Supplement 1, Pages S18-S22)
    Abstract | Abstract + References | Full-Text PDF (385 KB)

  1. Chemotherapy in patients with castration-resistant prostate cancer
    Hielke J. Meulenbeld, Paul Hamberg, Ronald de Wit
    European Journal of Cancer
    September 2009 (Vol. 45Supplement 1, Pages 161-171)
    Full Text | Full-Text PDF (344 KB)

  1. Current perspective – Trastuzumab , 01 December 2008
    Peter S. Hall, David A. Cameron
    European Journal of Cancer
    January 2009 (Vol. 45, Issue 1, Pages 12-18)
    Abstract | Full Text | Full-Text PDF (529 KB)
display abstract citation download email a colleague
Display:

  Viewing 1-20  of 1,576 results   Next 20>

Results Page:  [1]  2  3  4  5  6  7  >

New Search | Edit Search | Save Search | Save Search as an E-mail Alert

Advertisement

Copyright © 2009 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us |
The content on this site is intended for health professionals.